Assessment of a glycated hemoglobin point-of-care analyzer (A1CNow+) in comparison with an immunoturbidimetric method
a diagnostic accuracy study
Keywords:
Hemoglobin A, glycosylated, Point-of-care systems, Technology assessment, biomedical, Diabetes mellitus, Primary health careAbstract
CONTEXT AND OBJECTIVE: To monitor glycemic control in diabetic patients, regular measurement of glycated hemoglobin (HbA1c) is recommended, but this can be difficult in remote places without access to laboratories. Portable point-of-care testing devices can prove a useful alternative. Our study aimed to assess the performance of one of them: A1CNow+, from Bayer. DESIGN AND SETTING: Cross-sectional accuracy study conducted at a university hospital in Brazil. METHODS: We made three successive measurements of capillary HbA1c using the A1CNow+ in 55 diabetic volunteers, while the same measurement was made on venous blood using the hospital reference method (Vitros 5,1 FS). We used the Bland-Altman graphical method to assess the A1CNow+ in relation to the Vitros 5,1 FS method. We also evaluated clinical usefulness by calculating the sensitivity and specificity of A1CNow+ for detecting patients with HbA1c lower than 7%, which is the usual limit for good glycemic control. RESULTS: The coefficient of variation between repeat testing for the A1CNow+ was 3.6%. The mean differ- ence between A1CNow+ and Vitros 5,1 FS was +0.67% (95% confidence interval, CI: +0.52 to +0.81). The agreement limits of our Bland-Altman graph were -0.45 (95% CI: -0.71 to -0.19) and +1.82 (95% CI: +1.52 to +2.05). The sensitivity and specificity in relation to the 7% limit were respectively 100% and 67.7%. CONCLUSIONS: Although the A1CNow+ had good sensitivity, its accuracy was insufficient for use as a replacement for laboratory measurements of HbA1c, for glycemic control monitoring in diabetic patients.
Downloads
References
International Diabetes Federation. IDF Diabetes Atlas. 5th ed., 2012 Update. Available from: http://www.idf.org/sites/default/files/5E_IDFAtlasPoster_2012_EN.pdf. Accessed in 2014 (Sep 10).
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Secretaria de Gestão Estratégica e Participativa. Vigitel Brasil 2010: vigilância de fatores de risco e proteção para doenças crônicas por inquérito telefônico/Ministério da Saúde, Secretaria de Vigilância em Saúde, Secretaria de Gestão Estratégica e Participativa. Brasilia: Ministério da Saúde; 2011. Available from: http://biavati.files.wordpress.com/2014/05/vigitel_2010.pdf. Accessed in 2014 (Sep 10).
Cesse EA, Carvalho EF, Souza WV, Luna CF. Tendência da mortalidade por diabetes melito no Brasil: 1950 a 2000 [Mortality trends by the diabetes mellitus in Brazil: 1950 to 2000]. Arq Bras Endocrinol Metabol. 2009;53(6):760-6.
Mattos PE, Luz LL, Santiago LM, Mattos IE. Tendência da mortalidade por diabetes melito em capitais brasileiras, 1980-2007 [Trends in mortality of diabetes mellitus patients in Brazilian capitals, 1980-2007]. Arq Bras Endocrinol Metabol. 2012;56(1):39-46.
Brasil. Portal da Saúde SUS. Cidadão, entenda o SUS. Available from: http://portalsaude.saude.gov.br/index.php/cidadao/entenda-o-sus. Accessed in 2014 (Dec 16).
Brasil. Ministério da Saúde. Secretaria de Políticas de Saúde. Departamento de Ações Programáticas Estratégicas. Plano de reorganização da atenção à hipertensão arterial e ao diabetes mellitus: hipertensão arterial e diabetes mellitus/Departamento de Ações Programáticas Estratégicas. Brasilia: Ministério da Saúde; 2001. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/miolo2002.pdf. Accessed in 2014 (Sep 10).
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-86.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care. 2010;33 Suppl 1:S11-61.
National Glycohemoglobin Standardization Program. Harmonizing Hemoglobin A1c Testing. More About HbA1c. Clinical use. Available from: http://www.ngsp.org/ADA.asp. Accessed in 2014 (Sep 11).
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-10.
Price CP. Point of care testing. BMJ. 2001;322(7297):1285-8.
Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care. 1999;22(11):1785-9.
Miller CD, Barnes CS, Phillips LS, et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care. 2003;26(4):1158-63.
Gialamas A, St John A, Laurence CO, Bubner TK; PoCT Management Committee. Point-of-care testing for patients with diabetes, hyperlipidaemia or coagulation disorders in the general practice setting: a systematic review. Fam Pract. 2010;27(1):17-24.
Yager P, Domingo GJ, Gerdes J. Point-of-care diagnostics for global health. Annu Rev Biomed Eng. 2008;10:107-44.
Martin DD, Shephard MD, Freeman H, et al. Point-of-care testing of HbA1c and blood glucose in a remote Aboriginal Australian community. Med J Aust. 2005;182(10):524-7.
Martin CL. Quality control issues in point of care testing. Clin Biochem Rev. 2008;29 Suppl 1:S79-82.
Bode BW, Irvin BR, Pierce JA, Allen M, Clark AL. Advances in hemoglobin A1c point of care technology. J Diabetes Sci Technol. 2007;1(3):405-11.
Little RR, Lenters-Westra E, Rohlfing CL, Slingerland R. Point-of-care assays for hemoglobin A(1c): is performance adequate? Clin Chem. 2011;57(9):1333-4.
Sacks DB, Arnold M, Bakris GL, et al. Executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011;57(6):793-8.
Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010;56(1):44-52.
Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002;48(3):436-72.
Arrendale JR, Cherian SE, Zineh I, Chirico MJ, Taylor JR. Assessment of glycated hemoglobin using A1CNow+ point-of-care device as compared to central laboratory testing. J Diabetes Sci Technol. 2008;2(5):822-7.
